Literature DB >> 18093473

Therapeutic targeting of the alpha-secretase pathway to treat Alzheimer's disease.

Can Zhang1, Aleister J Saunders.   

Abstract

Alzheimer's disease (AD) is a progressive and degenerative disorder pathophysiologically characterized by the accumulation of beta-amyloid peptides (A-beta) in the brain. A-beta is indicated to be the primary agent in the pathogenesis of AD. A-beta is generated from the amyloid precursor protein (APP) via two proteolytic enzymes, beta- and gamma-secretases. Alpha-secretase conducts an alternative proteolytic cleavage that prevents A-beta production and accumulation. Elevating levels of alpha-secretase cleavage, therefore, is a potential therapeutic strategy to treat AD.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18093473

Source DB:  PubMed          Journal:  Discov Med        ISSN： 1539-6509            Impact factor:   2.970


  9 in total

1.  Familial Alzheimer's disease mutations in presenilin 1 do not alter levels of the secreted amyloid-beta protein precursor generated by beta-secretase cleavage.

Authors:  Can Zhang; Andrew Browne; Doo Yeon Kim; Rudolph E Tanzi
Journal:  Curr Alzheimer Res       Date:  2010-02       Impact factor: 3.498

2.  Curcumin decreases amyloid-beta peptide levels by attenuating the maturation of amyloid-beta precursor protein.

Authors:  Can Zhang; Andrew Browne; Daniel Child; Rudolph E Tanzi
Journal:  J Biol Chem       Date:  2010-07-09       Impact factor: 5.157

3.  Natural Modulators of Amyloid-Beta Precursor Protein Processing.

Authors:  C Zhang; R E Tanzi
Journal:  Curr Alzheimer Res       Date:  2012-09-13       Impact factor: 3.498

4.  Amyloid-β production via cleavage of amyloid-β protein precursor is modulated by cell density.

Authors:  Can Zhang; Andrew Browne; Jason R Divito; Jesse A Stevenson; Donna Romano; Yuanlin Dong; Zhongcong Xie; Rudolph E Tanzi
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

5.  Levels of amyloid-beta-42 and CSF pressure are directly related in patients with Alzheimer's disease.

Authors:  Tommaso Schirinzi; Giulia Di Lazzaro; Giulia Maria Sancesario; Vito Luigi Colona; Eugenia Scaricamazza; Nicola Biagio Mercuri; Alessandro Martorana; Giuseppe Sancesario
Journal:  J Neural Transm (Vienna)       Date:  2017-09-02       Impact factor: 3.575

6.  Loss of function of ATXN1 increases amyloid beta-protein levels by potentiating beta-secretase processing of beta-amyloid precursor protein.

Authors:  Can Zhang; Andrew Browne; Daniel Child; Jason R Divito; Jesse A Stevenson; Rudolph E Tanzi
Journal:  J Biol Chem       Date:  2010-01-22       Impact factor: 5.157

7.  Soluble Gamma-secretase Modulators Attenuate Alzheimer's β-amyloid Pathology and Induce Conformational Changes in Presenilin 1.

Authors:  Frank Raven; Joseph F Ward; Katarzyna M Zoltowska; Yu Wan; Enjana Bylykbashi; Sean J Miller; Xunuo Shen; Se Hoon Choi; Kevin D Rynearson; Oksana Berezovska; Steven L Wagner; Rudolph E Tanzi; Can Zhang
Journal:  EBioMedicine       Date:  2017-09-04       Impact factor: 8.143

8.  Association of the Protein-Quality-Control Protein Ubiquilin-1 With Alzheimer's Disease Both in vitro and in vivo.

Authors:  Can Zhang; Shivangi M Inamdar; Swathi Swaminathan; Daniel R Marenda; Aleister J Saunders
Journal:  Front Neurosci       Date:  2022-03-17       Impact factor: 4.677

Review 9.  Novel roles of amyloid-beta precursor protein metabolites in fragile X syndrome and autism.

Authors:  C J Westmark; D K Sokol; B Maloney; D K Lahiri
Journal:  Mol Psychiatry       Date:  2016-08-30       Impact factor: 15.992
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.